Corporate
Aymed İlaç Sanayi is a pharmaceutical manufacturer that has operated in Ankara since 1989 and whose capital is entirely Turkish. It manufactures in five therapy areas, principally urology and nephrology, and supplies the market under its own marketing authorisations.
A company that manufactures under its own authorisations and takes its own decisions.
Aymed İlaç carries out development, manufacturing and regulatory activities in-house. The marketing authorisation holder and the manufacturer are the same company, which means that responsibility across the chain from formulation to market supply rests in a single place.
Bringing medicines that are not available in Türkiye to the country through domestic manufacturing has been the company's core business since it was founded. Six authorised products are on the market today and nine marketing authorisation applications are under assessment.
Capital structure
Capital that is entirely Turkish. There is no foreign shareholding in the company's ownership structure. Investment decisions are taken in Türkiye and earnings remain in Türkiye.
How we are governed
The first and second generations of the founding family lead the business. The chain of decision-making is short; on technical matters, decisions are taken by managers who sit at the same table as the team doing the work.
Applications outside Türkiye
Our marketing authorisation applications are not limited to Türkiye. Application processes are under way for the Saudi Arabian and Russian markets.
Applications outside Türkiye →Our team
0+The number of people working in the manufacturing, quality, R&D, regulatory affairs and commercial functions.
Built on more than forty years of experience in the industry.
The company was founded in 1989; the founding family's experience in the pharmaceutical industry reaches back further than that date and spans more than forty years. That experience continues today with two generations working in the business at the same time.
In family companies, succession is often a point of rupture. At Aymed, two generations work side by side: institutional memory and new methods meet at the same table.
First generation
The generation that founded the company and laid the foundations of today's product range. It carries the institutional memory in manufacturing, regulatory affairs and industry relationships, and holds an active role in management.
Second generation
Holds an active role in expanding the R&D programmes, in marketing authorisation applications outside Türkiye and in carrying out manufacturing investments. The company's biological product and oncology programmes were started in this period.
How we work
A lean management structure: few layers of decision-making, decisions grounded in technical reasoning, and investment directed towards manufacturing capacity. The company prefers not to run more programmes than it can carry.
Bringing a medicine that is not available in Türkiye to the country has been our core business since the day we were founded.
Two sites in the Başkent Organised Industrial Zone in Ankara.
Manufacturing, quality control and storage are carried out in the same zone. Every step a product passes through, from granulation to dispatch, takes place at the company's own sites; no step is transferred to a third-party contract manufacturer.
Manufacturing site
- Address
- Malıköy Başkent OIZ 18th Street No: 16, Sincan / Ankara
- Scope
- Granulation, coating, tablet compression, capsule and sachet filling, packaging
- Batch size range
- 500 g – 500 kg
- Clean area
- Grade D
Second site and storage
- Address
- Malıköy Başkent OIZ 18th Street No: 33, Malıköy - Sincan / Ankara
- Scope
- Quality control laboratory, storage and distribution
- Cold chain
- 2–8 °C, continuously monitored
- Energy
- About half of the electricity used in production comes from the rooftop solar plant
Detailed site capabilities, the equipment park and the scope of the laboratory are set out on the Manufacturing and services → page.
What do we base our decisions on?
Access comes first
When we select development programmes, the first criterion is whether the product is available in Türkiye. Rather than making another version of a product that already exists, we prefer to make one that is not available.
Only as many programmes as we can carry
We keep the number of programmes running at any one time to a figure that our quality and regulatory teams can genuinely follow. The narrow width of our pipeline is a deliberate choice.
Records, not claims
Every manufacturing and quality control step is documented. If we describe a capability, there is a record behind it that demonstrates it.